Related Experiment Video
Updated: Jul 3, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Efavirenz concentrations in HIV-infected patients with and without viral hepatitis
Sofia A Pereira1, Umbelina Caixas, Teresa Branco
1Department of Pharmacology, Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal.
Aims:
Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included.
Methods:
A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period.
Results:
No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 +/- 1.91 mg l(-1)) vs. co-infected individuals (2.37 +/- 0.37 mg l(-1)).
Conclusion:
It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Hepatic Drug Excretion: Influencing Factors
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

